Results 191 to 200 of about 2,297,328 (417)
HELIN Access Services Affinity Group minutes for 10/18/12
Minutes of the Access Services Affinity Group of the HELIN Consortium for October ...
HELIN Consortium. Access Services Affinity Group
core
ABSTRACT Objective Cognitive decline is a disabling and variable feature of Parkinson disease (PD). While cholinergic system degeneration is linked to cognitive impairments in PD, most prior research reported cross‐sectional associations. We aimed to fill this gap by investigating whether baseline regional cerebral vesicular acetylcholine transporter ...
Taylor Brown +6 more
wiley +1 more source
Well-played and well-debated: Understanding perspective in contested affinity spaces
Sean C. Duncan
openalex +1 more source
Data Ranking and Clustering via Normalized Graph Cut Based on Asymmetric Affinity [PDF]
Olexiy Kyrgyzov +4 more
openalex +1 more source
HELIN E-Resources Affinity Group minutes for 11/19/2015
Minutes of the E-Resources Affinity Group of the HELIN Consortium for November 19, 2015.
HELIN Consortium. E-Resources Affinity Group
core
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan +5 more
wiley +1 more source
Purification of the human plasma alpha2‐SH glycoprotein by zinc chelate affinity chromatography [PDF]
J. P. Lebreton
openalex +1 more source
HELIN E-Resources Affinity Group minutes for 11/08/12
Minutes of the E-Resources Affinity Group of the HELIN Consortium for November ...
HELIN Consortium. E-Resources Affinity Group
core
Efficacy of Inebilizumab in N‐MOmentum Trial Participants With or Without Prior Immunosuppressants
ABSTRACT This post hoc analysis examined the impact of prior immunosuppressants on the long‐term efficacy and safety of inebilizumab, a cluster of differentiation 19+ B‐cell–depleting monoclonal antibody, in participants with aquaporin‐4–seropositive neuromyelitis optica spectrum disorder from the N‐MOmentum trial (NTC02200770).
Bruce A. C. Cree +9 more
wiley +1 more source

